Patent case.Amgen Inc. sued Roche Holding AG, accusing the drug maker of infringing on six patents covering its Epogen anemia anemia (ənē`mēə), condition in which the concentration of hemoglobin in the circulating blood is below normal. Such a condition is caused by a deficient number of erythrocytes (red blood cells), an abnormally low level of hemoglobin treatment. Thousand Oaks-based Amgen said the suit, filed in U.S. District Court in Boston, seeks an injunction preventing the manufacturing or sale of recombinant recombinant /re·com·bi·nant/ (re-kom´bi-nant) 1. the new entity (e.g., gene, protein, cell, individual) that results from genetic recombination. 2. pertaining or relating to such an entity. See also under DNA. human erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production , including "pegylated" versions that last longer in the body. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion